Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose versus standard-dose intravenous thiamine for alcohol-dependent inpatients at risk of subclinical Wernicke-Korsakoff syndrome
ACTRN12617001182381Phase 4Completed
- Sponsor
- Prof Stephen Bowden
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of thiamine in Wernicke-Korsakoff syndrome (WKS) and alcohol use disorder (AUD) (2 arms), sponsored by Prof Stephen Bowden. Primary endpoints: Working memory, Eye movement abnormalities total score and 1 more. Started Feb 2013; status: completed.
02
Drugs
thiamine
03
Conditions
Wernicke-Korsakoff syndrome (WKS)alcohol use disorder (AUD)
Beyond the preview
Go deeper on ACTRN12617001182381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001182381.